These include connecting cancers with HRD or STAG2 deficiency with PARP inhibitors, epigenetic dysregulation with histone deacetylase or EZH2 inhibitors, and DNA checkpoint abnormalities with ATM or ATR inhibitors, to name a few. Here, STAG2 is linked to cancer.